Metastatic Carcinoma
8
0
0
4
Key Insights
Highlights
Success Rate
67% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 74/100
25.0%
2 terminated out of 8 trials
66.7%
-19.8% vs benchmark
0%
0 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (8)
Stereotactic MRI-guided Adaptive Radiation Therapy (SMART) in One Fraction
Immune Checkpoint Inhibitor and MR-guided SBRT for Limited Progressive Metastatic Carcinoma.
Hormone Receptor Positive endometrIal Carcinoma Treated by Dual mTORC1/mTORC2 Inhibitor and Anastrozole (VICTORIA)
Gut Microbiome in Fecal Samples From Patients With Metastatic Cancer Undergoing Chemotherapy or Immunotherapy
Temozolomide in Preventing Brain Metastases in Small Cell Lung Cancer
α-TEA in Advanced Cancer
Study of Docetaxel and Gemcitabine in Metastatic Esophageal Squamous Cell Cancer
Radiation Stent Versus Self-expanding Metallic Stents (SEMS) for Palliative Treatment of Malignant Biliary Stricture